Functional Role of Phosphodiesterase 3 in Cardiomyocyte Apoptosis
Open Access
- 17 May 2005
- journal article
- research article
- Published by Wolters Kluwer Health in Circulation
- Vol. 111 (19) , 2469-2476
- https://doi.org/10.1161/01.cir.0000165128.39715.87
Abstract
Background— Myocyte apoptosis plays an important role in pathological cardiac remodeling and the progression of heart failure. cAMP signaling is crucial in the regulation of myocyte apoptosis and cardiac remodeling. Multiple cAMP-hydrolyzing phosphodiesterases (PDEs), such as PDE3 and PDE4, coexist in cardiomyocytes and elicit differential temporal/spatial regulation of cAMP signaling. However, the role of PDE3 and PDE4 in the regulation of cardiomyocyte apoptosis remains unclear. Although chronic treatment with PDE3 inhibitors increases mortality in patients with heart failure, the contribution of PDE3 expression/activity in heart failure is not well known. Methods and Results— In this study we report that PDE3A expression and activity were significantly reduced in human failing hearts as well as mouse hearts with chronic pressure overload. In primary cultured cardiomyocytes, chronic inhibition of PDE3 but not PDE4 activity by pharmacological agents or adenovirus-delivered antisense PDE3A promoted cardiomyocyte apoptosis. Both angiotensin II (Ang II) and the β-adrenergic receptor agonist isoproterenol selectively induced a sustained downregulation of PDE3A expression and induced cardiomyocyte apoptosis. Restoring PDE3A via adenovirus-delivered expression of wild-type PDE3A1 completely blocked Ang II– and isoproterenol-induced cardiomyocyte apoptosis, suggesting the critical role of PDE3A reduction in cardiomyocyte apoptosis. Moreover, we defined a crucial role for inducible cAMP early repressor expression in PDE3A reduction–mediated cardiomyocyte apoptosis. Conclusions— Our results suggest that PDE3A reduction and consequent inducible cAMP early repressor induction are critical events in Ang II– and isoproterenol-induced cardiomyocyte apoptosis and may contribute to the development of heart failure. Drugs that maintain PDE3A function may represent an attractive therapeutic approach to treat heart failure.Keywords
This publication has 38 references indexed in Scilit:
- PI3Kγ Modulates the Cardiac Response to Chronic Pressure Overload by Distinct Kinase-Dependent and -Independent EffectsCell, 2004
- Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III GuidelinesCirculation, 2004
- Fluorescence Resonance Energy Transfer–Based Analysis of cAMP Dynamics in Live Neonatal Rat Cardiac Myocytes Reveals Distinct Functions of Compartmentalized PhosphodiesterasesCirculation Research, 2004
- Cyclic AMP Promotes cAMP-responsive Element-binding Protein-dependent Induction of Cellular Inhibitor of Apoptosis Protein-2 and Suppresses Apoptosis of Colon Cancer Cells through ERK1/2 and p38 MAPKPublished by Elsevier ,2004
- Dual Inhibition of β-Adrenergic and Angiotensin II Receptors by a Single AntagonistCirculation, 2003
- Cyclic Nucleotide Phosphodiesterase Activity, Expression, and Targeting in Cells of the Cardiovascular SystemMolecular Pharmacology, 2003
- Inducible cAMP Early Repressor (ICER) Is a Negative-Feedback Regulator of Cardiac Hypertrophy and an Important Mediator of Cardiac Myocyte Apoptosis in Response to β-Adrenergic Receptor StimulationCirculation Research, 2003
- Congestive Heart FailureAmerican Journal of Cardiovascular Drugs, 2002
- Adrenergic regulation of cardiac myocyte apoptosisJournal of Cellular Physiology, 2001
- Dilated cardiomyopathy in transgenic mice expressing a dominant-negative CREB transcription factor in the heart.Journal of Clinical Investigation, 1998